v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Rental income $ 3,684,044 $ 4,032,429
Fees and other income 88,756 92,755
Total revenue 3,772,800 4,125,184
Costs and expenses:    
Rental operating costs 1,544,441 1,612,642
General and administrative 1,673,823 1,661,978
Depreciation and amortization 998,969 1,244,104
Impairment of goodwill and real estate assets 524,373 26,943
Total costs and expenses 4,741,606 4,545,667
Other income (expense):    
Net gain (loss) in Conduit Pharmaceuticals marketable securities (see Note 9) 1,985 (176,658)
Interest and other income, net 5,149 5,149
Gain on sales of real estate, net 172,096 4,453,968
Gain on disposition of assets and liabilities, net 3,416,501 0
Income tax (expense) benefit (18,057) 25,409
Total other income (expense), net 1,527,600 2,797,398
Net income 558,794 2,376,915
Less: Income attributable to noncontrolling interests (117,885) (111,563)
Net income attributable to Presidio Property Trust, Inc. stockholders 440,909 2,265,352
Less: Series D Preferred Stock declared dividends 0 (579,575)
Less: Series D Preferred Stock undeclared dividends in arrears (570,541) 0
Net loss attributable to Presidio Property Trust, Inc. common stockholders $ (129,632) $ 1,685,777
Net loss per share attributable to Presidio Property Trust, Inc. common stockholders:    
Basic & Diluted (in dollars per share) $ (0.1) $ 1.31
Weighted average number of common shares outstanding - basic & dilutive (in shares) 1,314,159 1,283,432
Mortgage Notes [Member]    
Other income (expense):    
Interest expense - mortgage notes $ (2,050,074) $ (1,510,470)